Aficamten Poised for Best-in-Class Status in oHCM Treatment with Anticipated Phase 3 Data and Promising Trial Results
Analyst Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Cytokinetics (CYTK – Research Report) and keeping the price target at ...
Investing10d
Cytokinetics stock keeps H.C. Wainwright Buy rating, well-positioned and funded
Additionally, the company is advancing several clinical trials that could expand treatment labels, such as the Phase 3 MAPLE trial comparing aficamten to metoprolol monotherapy in oHCM.
Investing9d
Cytokinetics stock keeps H.C. Wainwright Buy rating, well-positioned and funded
Additionally, the company is advancing several clinical trials that could expand treatment labels, such as the Phase 3 MAPLE trial comparing aficamten to metoprolol monotherapy in oHCM. The company's ...
Mena FN11d
Cytokinetics Announces 2025 Corporate Milestones And Vision 2030
Aficamten is also being evaluated in additional ... our ability to timely report the results of the MAPLE-HCM trial, and our ability achieve any element of our Vision 2030. Such statements are ...
Investing16d
Cytokinetics' SWOT analysis: aficamten progress boosts stock outlook
The MAPLE-HCM trial, which is evaluating aficamten as monotherapy, is expected to complete enrollment in the third quarter of 2024, with results anticipated in the first half of 2025. This study could ...